Therefore, chymase inhibitor may contribute to the prevention of hepatic fibrosis via inhibition of TGF-β activation by chymase inhibition and/or attenuation of TGF-β level via reduction of angiotensin II and mast cell proliferation. The gene discussed is CMA1; the disease is Hepatic fibrosis.